Swedish Experiences of THA Therapy in Alzheimer’s Disease

  • Henrik Nybäck
  • Arne Ahlin
  • Lars Gustafson
  • Lennart Minthon
Part of the Advances in Alzheimer Disease Therapy book series (AADT)


As in other western countries the mean age of the population in Sweden is increasing steadily and the number of individuals over 65 is growing rapidly. The mean surviving age of Swedes has become among the highest in the world, now 75 for men and 80 for women. This means that psychiatric problems of old age, such as the dementia disorders, has become a common concern for the health care system as well as for the whole community. Alzheimer’s disease is the most prevalent dementing illness in the western world, responsible for at least 50% of all severe dementing conditions.


Senile Dementia Placebo Period Alzheimer Therapy Dementia Disorder Rank Order Coefficient 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Adem A, Jossan SS and Oreland L (1989): Tetrahydroaminoacridine inhibits human and rat brain monoamine oxidase. Neurosci Lett 107:313–317.CrossRefGoogle Scholar
  2. Ahlin A, Nybäck H, Junthe T, Ahman G and Nordgren I (1991): Tetra-hydroaminoacridine in Alzheimer’s dementia: Clinical and biochemical results of a double-blind crossover trial. Human Psychopharmacol (In Press).Google Scholar
  3. Bartus RT, Dean III RL, Beer B and Lippa AS (1982): The cholinergic hypothesis of geriatric memory dysfunction. Science 217:408–417.CrossRefGoogle Scholar
  4. Benveniste D, Hemmingsen L and Juul P (1967): Tacrine inhibition of serum cholinesterase and prolonged succinylcholine action. Acta Anaesthesiol Scand 11:297–309.CrossRefGoogle Scholar
  5. Bowen DM, Smith CB, White P and Davison AN (1976): Neurotransmitter-related enzymes and indices of hypoxia in senile dementia and other abiotrophies. Brain 99:459–496.CrossRefGoogle Scholar
  6. Chatellier G and Lacomblez L (1990): Tacrine (tetrahydroaminoacridine; THA) and lecithin in senile dementia of the Alzheimer type: a multicentre trial. Brit Med J 300:495–499.CrossRefGoogle Scholar
  7. Christie JE (1982): Physostigmine and arecoline infusions in Alzheimer’s disease. In: Alzheimer’s disease: A report of progress in research. (Aging, Vol. 19), Corkin S, Davis KL, Growdon JH, Usdin E and Wurtman RJ, eds. New York: Raven Press, pp. 413–419.Google Scholar
  8. Coyle JT, Price DL and DeLong MR (1983): Alzheimer’s disease: a disorder of cortical cholinergic innervation. Science 219:1184–90.CrossRefGoogle Scholar
  9. Davies B, Andrewes D, Stargatt R, Ames D, Tuckwell V and Davis S (1989): Tacrine in Alzheimer’s disease. The Lancet 2:163–164.CrossRefGoogle Scholar
  10. Davies P and Maloney AJF (1976): Selective loss of central cholinergic neurons in Alzheimer’s disease. The Lancet 2:1403.CrossRefGoogle Scholar
  11. Davis KL and Mohs RC (1982): Enhancement of memory processes in Alzheimer’s disease with multiple-dose intravenous physostigmine. Am J Psychiat 139:1421–1424.Google Scholar
  12. Drukarch B, Leysen JE and Stoof, JC (1988): Further analysis of the neuropharmacological profile of 9-amino-l,2,3,4-tetrahydroacridine (THA), an alleged drug for the treatment of Alzheimer’s disease. Life Sci 42:1011–1017.CrossRefGoogle Scholar
  13. Forsyth DR, Wilcock GK, Morgan RA, Truman CA, Ford JM and Roberts CJC (1989): Pharmacokinetics of tacrine hydrochloride in Alzheimer’s disease. Clin Pharmacol Ther 46:634–641.CrossRefGoogle Scholar
  14. Gauthier S, Bouchard R, Lamontagne A, Bailey P, Bergmann H, Ratner J, Tesfaye Y, St-Martin M et al. (1990): Tetrahydro-aminoacridine-Lecithin combination treatment in patients with intermediate-stage Alzheimer’s disease. New Engt J Med 322:1272–1276.CrossRefGoogle Scholar
  15. Gustafson L, Edvinsson L, Dahlgren N, Hagberg B, Risberg J, Rosen I and Fernö H (1987): Intravenous physostigmine treatment of Alzheimer’s disase evaluated by psychometric testing, regional cerebral bloodflow (rCBF) measurement and EEG. Psychopharmacol 93:31–35.CrossRefGoogle Scholar
  16. Hartvig P, Askmark H, Aquilonius SM, Wiklund L and Lindström B (1990): Clinical pharmacokinetics of intravenous and oral 9-amino-l,2,3,4-tetra-hydroacridine, tacrine. Europ J Clin Pharmacol 38:259–263.CrossRefGoogle Scholar
  17. Heilbronn E (1961): Inhibition of cholinesterase by tetrahydroaminoacridine. Acta Chem Scand 15:1386–1390.CrossRefGoogle Scholar
  18. Minthon L, Dalfelt G, Gustafson L, Hagberg B, Nilsson K, Rosen I and Risberg J (1991): Oral tetrahydroaminoacridine (THA) and lecithin treatment of Alzheimer’s disease. (In Manuscript).Google Scholar
  19. Mohs RC, Davis BM, Johns CA, Mathé AA, Greenwald BS, Horvath TB and Davis KL (1985): Oral physostigmine treatment of patients with Alzheimer’s disease. Am J Psychiat 142:28–33.Google Scholar
  20. Muramoto O, Sugishita M, Sugita H and Toyokura Y (1979): Effect of physostigmine on constructional and memory tasks in Alzheimer’s disease. Arch Neurol 36:501–503.CrossRefGoogle Scholar
  21. Nilsson L, Adem A, Hardy J, Winblad B and Nordberg A (1987): Do tetra-hydroaminoacridine (THA) and physostigmine restore acetylcholine release in Alzheimer brains via nicotinic receptors? J Neural Transm 70:357–368.CrossRefGoogle Scholar
  22. Nybäck H, Nyman H, Blomqvist G, Sjögren I and Stone-Elander S (1991): Brain metabolism in Alzheimer’s dementia: Studies of HC-deoxyglucose accumu-lation, CSF monoamine metabolites and neuropsychological test performance in patients and healthy subjects. J Neurol Neurosurg Psychiat (In Press).Google Scholar
  23. Nybäck H, Nyman H, Öhman G, Nordgren I and Lindström B (1988): Preliminary experiences and results with THA for the amelioration of symptoms of Alzheimer’s disease. In: Current Research in Alzheimer Therapy, Giacobini E and Becker R, eds. New York: Taylor and Francis, pp. 231–236.Google Scholar
  24. Pearce BD and Potter LT (1988): Effects of tetrahydroaminoacridine on Ml and M2 muscarine receptors. Neurosci Lett 88:281–285.CrossRefGoogle Scholar
  25. Peters BH and Levin HS (1979): Effects of physostigmine and lecithin on memory in Alzheimer disease. Ann Neurol 6:219–221.CrossRefGoogle Scholar
  26. Perry EK, Tomlinson BE, Blessed G, Bergmann K, Gibson PH and Perry RH (1978): Correlation of cholinergic abnormalities with senile plaques and mental test scores in senile dementia. Brit Med J 2:1457–1459.CrossRefGoogle Scholar
  27. Perry EK, Smith CJ, Court JAG, Bonham JR, Rodway M and Atack JR (1988): Interaction of 9-amino-l,2,3,4-tetrahydroaminoacridine (THA) with human cortical nicotinic and muscarinic receptor binding in vitro. Neurosci Lett 91:211–216.CrossRefGoogle Scholar
  28. Risberg J, Gustafson L and Brun A (1990): High resolution regional cerebral blood flow measurements in Alzheimer’s disease and other dementia disorders. In: Alzheimer’s Disease. Epidemiology, Neuropathology, Neurochemistry and Clinics. Maurer K, Riederer P and Beckmann H, eds. Berlin: Springer-Verlag, pp. 510–516.Google Scholar
  29. Sahakian BJ (1988): Cholinergic drugs and human cognitive performance. In: Handbook of Psychopharmacology, Iversen LL, Iversen SD and Snyder SH, eds. New York: Plenum Press, pp. 393–424.CrossRefGoogle Scholar
  30. Summers WK, Viesselman JO, Marsh GM and Candelora K (1981): Use of THA in the treatment of Alzheimer-like dementia: Pilot study in twelve patients. Biol Psychiat 16:145–153.Google Scholar
  31. Summers WK, Majovski LV, Marsh GM, Tachiki K and Kling A (1986): Oral tertrahydroaminoacridine in long-term treatment of senile dementia, Alzheimer type. New Engl J Med 315:1241–45.CrossRefGoogle Scholar
  32. Summers WK, Tachiki KH and Kling A (1989): Tacrine in the treatment of Alzheimer’s disease. A clinical update and recent pharmacological studies. Eur Neurol 29(suppl):28–32.CrossRefGoogle Scholar
  33. Thal LJ, Fuld PA, Masur DM and Sharpless NS (1983): Oral physostigmine and lecithin improve memory in Alzheimer disease. Ann Neurol 13:491–496.CrossRefGoogle Scholar
  34. Whitehouse PJ, Martino AM, Antuono PG, Lowenstein PR, Coyle JT, Price DL and Kellar KJ (1986): Nicotinic acetylcholine binding sites in Alzheimer’s disease. Brain Res 371:146–151.CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 1991

Authors and Affiliations

  • Henrik Nybäck
    • 1
  • Arne Ahlin
    • 1
  • Lars Gustafson
    • 2
  • Lennart Minthon
    • 2
  1. 1.Department of Psychiatry and PsychologyKarolinska HospitalStockholmSweden
  2. 2.Department of PsychogeriatricsS:t Lars HospitalLundSweden

Personalised recommendations